Anebulo Pharmaceuticals Sets Date for Annual Meeting

Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) announced in a recent Form 8-K filing with the Securities and Exchange Commission that the company’s Board of Directors has scheduled its upcoming annual meeting of stockholders (the “Annual Meeting”). The event is slated to take place on April 4, 2025.

The specific time and location details of the Annual Meeting are yet to be finalized and will be disclosed in the Company’s proxy materials, as per the filing requirements with the SEC. Given that the scheduled date falls more than 30 days after the anniversary date of the Company’s 2023 annual stockholders meeting, the previous deadlines concerning stockholder proposal submissions are no longer applicable.

Anebulo Pharmaceuticals has provided revised deadlines for the submission of stockholder proposals in connection with the Annual Meeting. Stockholders aiming to propose items for the Annual Meeting must adhere to certain timelines. Proposals submitted pursuant to Rule 14a-8 will be considered timely for inclusion in the Company’s proxy statement and form of proxy for the Annual Meeting if received by February 22, 2025.

It is noteworthy that any public announcement of a change in the date of the Annual Meeting will not initiate a new timeframe for stockholder proposal submissions under Rule 14a-8. Furthermore, for any director nominations or proposals not intended for inclusion in the proxy materials as per Rule 14a-8, stockholders should provide timely notice within 10 days following the initial public announcement of the Annual Meeting date.

In compliance with universal proxy rules, stockholders intending to solicit proxies to support director nominees other than those proposed by the Company need to provide notice by February 22, 2025. This deadline is ten days following the filing of the Current Report on Form 8-K that disclosed the date of the Annual Meeting.

Richard Anthony Cunningham, the Chief Executive Officer of Anebulo Pharmaceuticals, signed the report on February 12, 2025, in accordance with the requirements of the Securities Exchange Act of 1934.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Anebulo Pharmaceuticals’s 8K filing here.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.